Diabetes, Metabolic Syndrome and Obesity (Feb 2020)
Lower Levels of Circulating Adiponectin in Elderly Patients with Metabolic Inflammatory Syndrome: A Cross-Sectional Study
Abstract
Lina Ma,1,* Yanhong Xu,1,2,* Yaxin Zhang,1 Tong Ji,1 Yun Li1 1Department of Geriatrics, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing 100053, People’s Republic of China; 2Department of Geriatrics, Miyun Teaching Hospital of Capital Medical University, Beijing 101500, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lina MaDepartment of Geriatrics, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, #45 Changchun Street, Xicheng District, Beijing 100053, People’s Republic of ChinaEmail [email protected]: Metabolic inflammation plays an important role in the pathogenesis of atherosclerosis, type 2 diabetes, non-alcoholic fatty liver disease, and obesity. The above metabolic disorders often coexist and are closely related with systemic low-grade inflammation. Metabolic inflammatory syndrome (MIS), a cluster of these four metabolic disorders, is a novel concept that is thought to be a better predictor of coronary heart disease than metabolic syndrome. Adiponectin is an adipokine that increases insulin sensitivity and antioxidation as well as has an anti-atherosclerosis effect. It is unclear whether adiponectin is associated with MIS. The objective of this study was to assess whether circulating adiponectin can be used as an indicator for MIS in elderly adults.Methods: A total of 136 elderly inpatients were divided into two groups: the MIS group and the non-MIS group. Characteristics, inflammatory markers, blood lipid metabolism, insulin resistance, and circulating adiponectin levels were assessed and compared between the two groups. Logistic regression analysis was used to explore the association between the associated factors and MIS.Results: MIS patients were more likely to have a higher body mass index, have a higher fasting blood glucose level, be smokers, have fundus arteriosclerosis, have lower levels of adiponectin (4044.90 ± 3906.82 ng/mL vs 8503.89 ± 3523.89 ng/mL, p < 0.001), and have higher levels of inflammation (white blood cell and C-reactive protein) than non-MIS patients. Multiple factor analysis showed that lower adiponectin levels (OR = 22.937, p < 0.001) were independently associated with MIS. Adiponectin levels were lower in the vascular disease (2673.29 ± 1930.05 ng/mL vs 7194.38 ± 4615.83 ng/mL, p = 0.001), atherosclerosis (2374.14 [1496.41– 4263.90] ng/mL vs 6037.48 [3865.61– 10,373.60] ng/mL, p < 0.001), and type 2 diabetes (2391.73 [1386.41– 4069.68] ng/mL vs 8916.03 [5801.14– 12,724.45] ng/mL, p < 0.001) subgroups than in the non-MIS group.Conclusion: Lower adiponectin levels in serum are associated with MIS. Low adiponectin may be used as a biomarker for atherosclerosis in patients with MIS.Keywords: metabolic inflammatory syndrome, adiponectin, atherosclerosis, type 2 diabetes, obesity, inflammation, elderly patients
